Company profile · Biotech & medical
ScinoPharm Taiwan
台灣神隆股份有限公司 · 1789
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
ScinoPharm Taiwan develops and manufactures active pharmaceutical ingredients and formulations, specializing in high-barrier technologies and focusing on areas such as oncology, cardiovascular, central nervous system, and metabolic diseases.[1]
The company provides contract development and manufacturing services, ranging from process development and clinical sample preparation to commercial mass production.[2]
Its global customers include international proprietary pharmaceutical companies and generic drug manufacturers.[2]
Based in Taiwan, the company is headquartered in Tainan.[3]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$163m | -47.4% | -47.2% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$72m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | ScinoPharm Taiwan, Ltd. |
|---|---|
| Chinese name | 台灣神隆股份有限公司 |
| Stock code | 1789 (TWSE) |
| Industry | Biotech & medical |
| Founded | 11 Nov 1997 |
| Listed | 29 Sep 2011 |
| Paid-in capital | NT$7.9bn |
| Chairman | 羅智先 |
| President | 盧麗安 |
| Headquarters | No. 1 , Nan-Ke 8th Road , Southern Taiwan Science Park, Shan-Hua, Tainan, Taiwan, R.O.C. |
| Website | https://www.scinopharm.com/tw |
| Official business description | 原料藥、針劑製劑之研發、產銷及相關產品之諮詢及技術服務業務 · 生物技術服務 · 國際貿易業 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- 台灣神隆股份有限公司 · website · retrieved 04 Nov 2026
- 公司簡介-台灣神隆股份有限公司 · website · retrieved 04 Nov 2026
- MOPS 公司基本資料 台灣神隆股份有限公司 · mops · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list